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Liothyronine prescribing in the UK has changed dramatically with widespread variation by 
clinical commissioning group and is strongly influenced by economic deprivation. 
Peter N Taylor, Salman Razvi, Ilaria Muller, John Wass, Colin M Dayan, Krishna Chatterjee and 
Kristien Boelaert  
 
Levothyroxine is commonly prescribed for hypothyroidism and its use is steadily increasing
1
. A 
subgroup of patients are dissatisfied on levothyroxine monotherapy
2
 and in some clinical trials, 
patients demonstrated preference for a combination of thyroxine and liothyronine. With clinical trials 
not showing clear-cut superiority, combination thyroid hormone therapy remains controversial
3
.  
However, acknowledging limitations (small size, short duration, inconsistent dosage) of previous 
studies, specialist society guidance recognises that a trial of liothyronine may be appropriate in 
selected patients
4
 and studies of genetic polymorphisms (e.g. Thr92AlaD2) may indicate specific 
patients to target.  In 2016, the 28-day NHS cost of liothyronine increased dramatically from ~£4·50 
to £258·19, resulting in widespread patient concern and media coverage
5
. Over this time the cost of 
levothyroxine has broadly remained unchanged. Clinicians are under increasing pressure to justify 
prescriptions and for many patients treatment has been discontinued or requires private sourcing. A 
parliamentary enquiry is ongoing. Given these changes in costs occurred uniquely in the NHS, these 
trends in T3 prescribing likely only apply to the UK. 
 
We analysed NHS England open prescribing data
6
, between 01/08/2013 and 01/07/2018, sequentially 
examining the monthly number and cost of NHS liothyronine prescriptions for each clinical 
commissioning group (CCG N=195). CCGs are responsible for commissioning healthcare services in 
their local area. In August 2013, the median number of monthly liothyronine prescriptions per CCG 
was 22 (IQR 12-38) falling to 17 (IQR 10-30) p<0·0001 by July 2018. Most marked prescribing 
changes in early 2016 coincided with substantial rise in costs (Figure 1). The total monthly cost of 
liothyronine prescriptions in August 2013 was £758,975 and this rose almost ten-fold to £7,018,679 
by July 2018, despite 122 CCGs prescribing less liothyronine.  
 
Between August 2013 and July 2018, there was a median 37% reduction in the ratio of liothyronine 
prescriptions per 1,000 levothyroxine prescription nationwide, with a maximum 32-fold reduction in 
one CCG. Widespread variation by CCG is now apparent, with a 49-fold difference in liothyronine 
prescriptions per 1,000 levothyroxine prescriptions. Analysis of CCG demographics showed that for 
each quintile increase in economic deprivation there were 0·21SD (95%CI -0·31, -0·11) p<0·001 
lower liothyronine prescriptions. An overview of current liothyronine prescribing by CCG is shown in 
Supplementary Figure 1 with changes from 2013-2018 shown in Supplementary Figure 2.   
 
Over this time period no major study or guideline has advocated a change in liothyronine prescribing. 
Thus, this substantial reduction in prescribing appears to have been largely driven by cost. Given the 
concerns raised by patients, this near 50-fold disparity between CCGs in prescribing liothyronine 
linked to deprivation status, is difficult to justify. Moreover, patients in more affluent areas may 
source liothyronine by private prescription, further exacerbating the inequality.  
 
Overall, current pricing of liothyronine has markedly reduced its prescription, engendered widespread 
variability in patients’ access to it and significantly increased its overall cost to the NHS. Furthermore 
patients may have turned to alternate sources of T3 such as Armour thyroid which contains a 
supraphysiologic ratio of T3:T4 and may have more adverse effects. Furthermore the rising cost of T3 
may adversely impact its availability for patients with thyroid cancer undergoing radioactive iodine 
treatment. Our findings support the need for urgent measures to reduce liothyronine’s NHS cost. 
Alternatively, if future, adequately-powered, randomised controlled trials strengthen the evidence-
base for liothyronine therapy, this may identify the cost-benefit equation for its use.  
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Figure legends 
 
Figure 1A 
Total cost and number of liothyronine prescriptions per 1000 T4 prescriptions 2013-2018 
 
Figure 1B 
Median number of liothyronine prescriptions per 1000 levothyroxine prescriptions by Index of 
Multiple Deprivation Quintile   
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